First Published Resveratrol Human Clinical Trial for Glucose Management

Share Article

A pilot resveratrol study that used Biotivia Transmax, has been published in the Journal of Gerontology. The study was carried out by the Albert Einstein Medical College into glucose tolerance and has come back with positive results that could prove useful for pre-diabetes and diabetes sufferers.

98%+ Trans-resveratrol

The results, published in the Journal of Gerontology by the Albert Einstein Medical College, reported that the study, undertaken using Biotivia's Transmax resveratrol, at doses of 1, 1.5 and 2 grams (2, 3 and 4 capsules) daily over a period of 4 weeks, resulted in two important positive findings for pre-diabetes and diabetes sufferers.

First, insulin sensitivity was increased. The potential benefit of this finding is that patients with diabetes may be able to manage their condition with either no insulin or fewer insulin injections if they also take a daily dose of resveratrol. In many cases this could mean that diet and exercise alone could be sufficient to maintain healthy blood sugar levels.

The second finding in this study was that the spikes of blood sugar which diabetics experience after consuming a meal containing sugar or other carbohydrates was greatly reduced. This is an important potential benefit for diabetics and pre diabetics because it prevent the damage such spikes cause to various organs and cells in the body.

Taken together these results point to a potentially safe and effective new way for the millions of diabetes patients and those who are glucose intolerate to significantly improve their quality of life. Dr Crandall, the study coordinator at the Albert Einstein Medical College, stated, “We were able to detect differences within the narrow dose range studied.”

The landmark study, which is the first of its type to be published in a major peer reviewed scientific journal, the Journal of Gerontology, validated resveratrol's potential value as a preventative and treatment for diabetics and persons with a condition called pre-diabetes that, over time, evolves into full fledged diabetes.

The group of 10 subjects which were given either 2 or 4 Transmax resveratrol capsules daily were all suffering from glucose intolerance, often an early indicator of impending Type 2 Diabetes. All ten subjects experienced significant improvement in their ability to tolerate glucose.

A further benefit of the Transmax over some of the more recent diabetes pharmaceutical treatments is the no side effects were detected and nor were any changes in body weight, blood lipids or blood pressure observed.

Dr. Crandall stated, “Together these results suggest that resveratrol shows promise as a new therapeutic strategy for and important and highly prevalent age-related metabolic disorder.

The study was funded by the National Institutes on Aging, the National Institutes of Health, and the Einstein Diabetes Research and Training Center. The resveratrol used in the study was a supplement named Transmax, manufactured by Biotivia LLC of New York.


(1) Resveratrol: Pilot Study supports cardio-metabolic benefits

(2) Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance

(3) Albert Einstein College of Medicine results

(4) Biotivia Transmax Resveratrol

About Biotivia LLC
Biotivia was established in 1992 in Vienna, Austria as a supplier of natural raw materials and biologically active botanics to the supplement and functional food industries and to researchers and scientific institutions worldwide. The company evolved into one of the world's leading developers and suppliers of unique science-based nutritional supplements and award winning skin care therapies, with most of their products centered around the use of concentrated resveratrol and complementary botanical extracts.

Biotivia presently has US offices in New York, Los Angeles, Kansas City and international offices in the UK, Spain, Austria, Denmark, Italy, Germany, Singapore, Xi'an, China and Mumbai, India.

Beyond its strong consumer base, the company currently supplies researchers, physicians and scientists at Harvard, Stanford, Yale, Georgetown, The Albert Einstein Medical Center, University of Texas, M.D. Anderson Cancer Center, Health Canada, and the University of California. Transmax and Bioforte in particular are being investigated by several major university medical schools as a possible treatment for a variety of conditions that seriously impair the health and well being of millions of people around the world. Biotivia most recently signed an agreement to supply Transmax to the University of Ferrara for use in three human clinical trials in Italy and Egypt on its possible use by Thalassemia sufferers as an alternative to the whole blood transfusions which such patients now require monthly. The Albert Einstein Medical College published a study which elucidated the beneficial effects of Biotivia’s proprietary resveratrol on glucose tolerance and mitochondria function in pre-diabetic subjects. Bioforte was also shown to more than double brain blood flow in a study done at the University of Northumbria in the UK.

Biotivia's resveratrol products, Transmax and Bioforte, have been independently assessed by Consumer Labs, the leading American quality watchdog, and were deemed both 'most potent' and 'best value'. Transmax has been certified as an investigational drug by the NIH, an endorsement of its safety and purity.

Most of Biotivia's supplements have been certified Vegan by the American Vegetarian Association.

Important Caveat: Neither Trans,ax nor any Biotivia product has been definitively shown to diagnose, prevent or cure any age related diseases. Transmax is not intended to diagnose, prevent, treat or cure any disease. Studies done in vitro and on animals do not always translate into the same biological effect when taken by human subjects. The statements herein have not been reviewed or approved by the US FDA. All Biotivia supplements are manufactured in state of the art government inspected pharmaceutical facilities in accordance with CGMP and USP standards.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

James Betz
Email >
Visit website